AbbVie News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

04.04.23	AbbVie to Host First-Quarter 2023 Earnings Conference Call (PR Newswire)
03.04.23	CoolSculpting® Elite Announces First Ever CoolMonth (PR Newswire)
29.03.23	Allergan Aesthetics* to showcase 360° approach to clinical practice, aesthetic products, and patients with expert-led symposia at AMWC 2023 (PR Newswire)
23.03.23	AbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical Trials in Systemic Lupus Erythematosus (PR Newswire)
23.03.23	AbbVie: Phase 3 Induction Study With Risankizumab Meets Endpoints (RTTNews)
23.03.23	Risankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis (PR Newswire)
22.03.23	AbbVie: FDA Requests Additional Information Related To NDA Review Of ABBV-951 (RTTNews)
22.03.23	AbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application (PR Newswire)
18.03.23	AbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® (risankizumab) in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor T... (PR Newswire)
15.03.23	AbbVie Partners with Award-Winning Redglass Pictures on New Film Shedding Light on the Hidden Struggles of Those Living with Eczema (PR Newswire)
13.03.23	AbbVie Showcases Strength of Dermatology Portfolio with New Data Presented at the 2023 AAD Annual Meeting (PR Newswire)
08.03.23	BOTOX® Cosmetic (onabotulinumtoxinA) Partners with IFundWomen to Help Close the Confidence Gap for Women Entrepreneurs (PR Newswire)
08.03.23	AbbVie to Present at the Barclays Global Healthcare Conference (PR Newswire)
28.02.23	AbbVie to Present at the Cowen 43rd Annual Health Care Conference (PR Newswire)
27.02.23	AbbVie Highlights Robust Gastroenterology Portfolio with New Analyses and Data in Inflammatory Bowel Diseases at the 18th Congress of European Crohn's and Colitis Organisation (ECCO) (PR Newswire)
27.02.23	AbbVie Gets Positive CHMP Opinion For Upadacitinib For Treatment Of Adults With Crohn's Disease (RTTNews)
27.02.23	AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Crohn's Disease (PR Newswire)
23.02.23	AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need (PR Newswire)
23.02.23	AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need (PR Newswire)
16.02.23	AbbVie Declares Quarterly Dividend (PR Newswire)
09.02.23	AbbVie Q4 Profit Decreases, but beats estimates (RTTNews)
09.02.23	AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results (PR Newswire)
25.01.23	Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023 (PR Newswire)
18.01.23	JUVÉDERM® VOLUX™ XC FOR IMPROVEMENT OF JAWLINE DEFINITION NOW AVAILABLE NATIONWIDE (PR Newswire)
17.01.23	SkinMedica® Launches Even & Correct (PR Newswire)
17.01.23	BioMed X Extends Research Collaboration With AbbVie On Immunology And Tissue Engineering (RTTNews)
10.01.23	AbbVie, Anima Biotech Collaborate To Develop MRNA Modulators In Oncology, Immunology Targets (RTTNews)
10.01.23	AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets (PR Newswire)
09.01.23	AbbVie's Qulipta Approved In Canada For Preventive Treatment Of Episodic Migraine In Adults (RTTNews)
06.01.23	AbbVie, Immunome Collaborate To Discover Multiple Novel Oncology Targets (RTTNews)
06.01.23	AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets (PR Newswire)
05.01.23	AbbVie to Host Fourth-Quarter 2022 Earnings Conference Call (PR Newswire)
03.01.23	AbbVie to Present at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire)
17.12.22	U.S. FDA Approves VRAYLAR® (cariprazine) as an Adjunctive Treatment for Major Depressive Disorder (PR Newswire)
16.12.22	AbbVie Submits SNDA For Linaclotide For Treatment Of Children, Adolescents (RTTNews)
16.12.22	AbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents 6 to 17 Years of Age (PR Newswire)
12.12.22	AbbVie Named to Dow Jones Sustainability World Index for 10th Straight Year (PR Newswire)
11.12.22	AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas (PR Newswire)
11.12.22	AbbVie Presents Data For Navitoclax Combination For JAK Inhibitor-Naïve Myelofibrosis Patients (RTTNews)
10.12.22	AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting for Investigational Navitoclax in Combination With Ruxolitinib for JAK Inhibitor-Naïve Myelofibrosis Patients (PR Newswire)
10.12.22	AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Adds to Robust IMBRUVICA® (ibrutinib) Science (PR Newswire)
06.12.22	AbbVie Signs License Agreement With HotSpot For Use Of IRF5 In Autoimmune Diseases (RTTNews)
06.12.22	AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline (PR Newswire)
06.12.22	AbbVie to Showcase Migraine Portfolio and Pipeline During the 16th European Headache Federation Congress (PR Newswire)
01.12.22	AbbVie Announces Provincial Reimbursement For RINVOQ For Rheumatoid Treatment (RTTNews)
23.11.22	AbbVie to Present at the Evercore ISI HealthCONx Conference (PR Newswire)
23.11.22	AbbVie: SKYRIZI (risankizumab) Gets EU Approval To Treat Moderate To Severe Active Crohn's Disease (RTTNews)
23.11.22	AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn's Disease (PR Newswire)
22.11.22	AbbVie Highlights Blood Cancer Data From Its Growing Oncology Pipeline at the 64th ASH Annual Meeting (PR Newswire)
22.11.22	AbbVie to Present at the Piper Sandler Healthcare Conference (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

11.11.24		Börse New York in Grün: S&P 500 zum Handelsende freundlich
11.11.24		Optimismus in New York: S&P 500 am Nachmittag mit Kursplus
11.11.24		NYSE-Handel: S&P 500 mittags freundlich
11.11.24		Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen
02.07.24		Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge
02.07.24		Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten
06.05.24		S&P 500-Titel AbbVie-Aktie: Mit dieser Dividende bereitet AbbVie Aktionären eine Freude
26.04.24		Gewinne in New York: S&P 500 am Nachmittag fester

11.11.24

Börse New York in Grün: S&P 500 zum Handelsende freundlich

11.11.24

Optimismus in New York: S&P 500 am Nachmittag mit Kursplus

11.11.24

NYSE-Handel: S&P 500 mittags freundlich

11.11.24

Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen

02.07.24

Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge

02.07.24

Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten

06.05.24

S&P 500-Titel AbbVie-Aktie: Mit dieser Dividende bereitet AbbVie Aktionären eine Freude

26.04.24

Gewinne in New York: S&P 500 am Nachmittag fester

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Logitech Intl	74.04	2.41 %	K V
ABB	52.12	1.68 %	K V
Geberit	552.80	1.32 %	K V
Alcon	78.04	1.19 %	K V
CieFinRichemont	129.05	1.10 %	K V
Swiss Life Hldg	686.00	-0.64 %	K V
Zurich Insur Gr	555.20	-1.00 %	K V
Holcim	90.66	-1.31 %	K V
Kuehne+Nagel Int	210.60	-1.31 %	K V
Novartis	90.10	-3.14 %	K V

Nachrichten zu AbbVie Inc

Aktien Top/Flop

AbbVie Peer Group Nachrichten

Meistgelesene Nachrichten